A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
Status:
Recruiting
Trial end date:
2022-10-22
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and
in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are
homozygous for the F508del mutation.